Invasive carcinoma of breast
Item
1. a histological confirmed invasive breast cancer
boolean
C0853879 (UMLS CUI [1])
Metastatic malignant neoplasm to brain Measurable Quantity | Tumor size T1 Nuclear magnetic resonance imaging gadolinium-enhanced | Metastatic malignant neoplasm to brain Measurable CT scan contrast | Metastatic Malignant Neoplasm to the Leptomeninges Cerebrospinal Fluid Positive
Item
2. patient with at least one measurable brain metastatic tumor (≧10mm on t1-weighted gadolinium enhanced mri or contrast-enhanced ct) or leptomeningeal metastasis with positive csf cytology study.
boolean
C0220650 (UMLS CUI [1,1])
C1513040 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0475440 (UMLS CUI [2,1])
C2697938 (UMLS CUI [2,2])
C0855566 (UMLS CUI [2,3])
C0220650 (UMLS CUI [3,1])
C1513040 (UMLS CUI [3,2])
C0742919 (UMLS CUI [3,3])
C1704231 (UMLS CUI [4,1])
C0007806 (UMLS CUI [4,2])
C1514241 (UMLS CUI [4,3])
Metastatic malignant neoplasm to brain Parenchymal | Disease Progression | Status post Whole brain radiation therapy | New Lesion Identification | CNS metastases Unresponsive to Whole brain radiation therapy | Imaging study
Item
3. patient whose brain parenchymal metastatic tumors either progress after wbrt, develop new lesions after wbrt, or cns metastatic tumor do not response to wbrt according to image study 3 months after treatment. patients with leptomeningeal metastasis does not necessarily need whole brain radiotherapy before enrollment.
boolean
C0220650 (UMLS CUI [1,1])
C4277702 (UMLS CUI [1,2])
C0242656 (UMLS CUI [2])
C0231290 (UMLS CUI [3,1])
C1520143 (UMLS CUI [3,2])
C2986548 (UMLS CUI [4])
C0686377 (UMLS CUI [5,1])
C0205269 (UMLS CUI [5,2])
C1520143 (UMLS CUI [5,3])
C1881134 (UMLS CUI [6])
HER2 Protein Overexpression | HER2 gene amplification | Treatment option | Lapatinib plus Capecitabine
Item
4. patients with her2/neu overexpression or amplification will be allowed but will be informed about other available treatment options such as lapatinib plus capecitabine.
boolean
C1515560 (UMLS CUI [1])
C1512127 (UMLS CUI [2])
C0683525 (UMLS CUI [3])
C1506770 (UMLS CUI [4,1])
C0332287 (UMLS CUI [4,2])
C0671970 (UMLS CUI [4,3])
Organ function Total | Bone Marrow Mature Neutrophils Present
Item
5. patients must have adequate organ and marrow reserve measured within 14 days prior to randomization as defined below:
boolean
C0678852 (UMLS CUI [1,1])
C0439810 (UMLS CUI [1,2])
C0005953 (UMLS CUI [2,1])
C1708947 (UMLS CUI [2,2])
Absolute neutrophil count
Item
absolute neutrophil count ≧1,000/mcl
boolean
C0948762 (UMLS CUI [1])
Platelet Count measurement
Item
platelets ≧75,000/mcl
boolean
C0032181 (UMLS CUI [1])
Serum total bilirubin measurement
Item
total bilirubin ≦ 1.5 x upper normal limit
boolean
C1278039 (UMLS CUI [1])
Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Secondary malignant neoplasm of liver
Item
ast(sgot)/alt(sgpt) ≦ 2.5 x upper normal limit; for patients with liver metastases ast(sgot)/alt(sgpt) ≦ 5 x is allowed
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
C0494165 (UMLS CUI [3])
Creatinine measurement, serum | Creatinine clearance measurement
Item
serum creatinine ≦ upper normal limit or creatinine clearance ≧50ml/min
boolean
C0201976 (UMLS CUI [1])
C0373595 (UMLS CUI [2])
Hemoglobin measurement
Item
hemoglobin≧8.0 gm/dl
boolean
C0518015 (UMLS CUI [1])
Activated Partial Thromboplastin Time measurement | International Normalized Ratio
Item
ptt ≦ upper normal limit; inr ≦ 1.5
boolean
C0030605 (UMLS CUI [1])
C0525032 (UMLS CUI [2])
Proteinuria | Urine protein test g/24h
Item
proteinuria ≤ 1+, if > 1+, urine protein must be ≦ 1 g/24 hours
boolean
C0033687 (UMLS CUI [1])
C0262923 (UMLS CUI [2,1])
C0439417 (UMLS CUI [2,2])
Age
Item
6. patient age 18 to 75 years
boolean
C0001779 (UMLS CUI [1])
Life Expectancy
Item
7. patient's life expectancy is more than 2 months
boolean
C0023671 (UMLS CUI [1])
ECOG performance status
Item
8. eastern cooperative oncology group performance status (ecog ps) of 0, 1, 2 or 3
boolean
C1520224 (UMLS CUI [1])
Childbearing Potential Pregnancy test negative
Item
9. all women of childbearing potential must have a negative pregnancy test obtained within 72 hours before starting therapy
boolean
C3831118 (UMLS CUI [1,1])
C0427780 (UMLS CUI [1,2])
Females & males of reproductive potential Contraceptive methods | Hormonal contraception | Contraception, Barrier | Sexual Abstinence
Item
10. patients with reproductive potential must use effective contraception (hormone or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 2 months after the completion of therapy
boolean
C4034483 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C2985296 (UMLS CUI [2])
C0004764 (UMLS CUI [3])
C0036899 (UMLS CUI [4])
Protocol Compliance | Informed Consent | Protocol Compliance Patient Representative | Informed Consent Patient Representative
Item
11. patients (or a surrogate) must be able to comply with study procedures and sign informed consent
boolean
C0525058 (UMLS CUI [1])
C0021430 (UMLS CUI [2])
C0525058 (UMLS CUI [3,1])
C0030701 (UMLS CUI [3,2])
C0021430 (UMLS CUI [4,1])
C0030701 (UMLS CUI [4,2])
bevacizumab | sorafenib | sunitinib | Targeted Therapy VEGF Signaling Pathway
Item
1. prior therapy with bevacizumab, sorafenib, sunitinib, or other vegf pathway-targeted therapy
boolean
C0796392 (UMLS CUI [1])
C1516119 (UMLS CUI [2])
C1176020 (UMLS CUI [3])
C2985566 (UMLS CUI [4,1])
C2984329 (UMLS CUI [4,2])
CNS metastases | Disease Progression | Cisplatin
Item
2. patients whose cns metastasis progressed or developed during prior cisplatin treatment
boolean
C0686377 (UMLS CUI [1])
C0242656 (UMLS CUI [2])
C0008838 (UMLS CUI [3])
Congenital bleeding diathesis | Blood Coagulation Disorder with Bleeding risk
Item
3. history or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding
boolean
C1856452 (UMLS CUI [1])
C0005779 (UMLS CUI [2,1])
C0332287 (UMLS CUI [2,2])
C3251812 (UMLS CUI [2,3])
Thrombosis
Item
4. history of thrombotic disorders
boolean
C0040053 (UMLS CUI [1])
Gastrointestinal Hemorrhage
Item
5. active gastrointestinal bleeding
boolean
C0017181 (UMLS CUI [1])
Intracranial Hemorrhage
Item
6. patients with a history of self-reported intra-cranial hemorrhage
boolean
C0151699 (UMLS CUI [1])
Clinical signs Gastrointestinal obstruction | Symptoms Gastrointestinal obstruction | Obstruction Requirement Parenteral fluids for hydration | Obstruction Requirement Parenteral Nutrition
Item
7. patients with clinical signs or symptoms of gastrointestinal obstruction and who require parenteral hydration and/or nutrition because of obstruction
boolean
C3540840 (UMLS CUI [1,1])
C0236124 (UMLS CUI [1,2])
C1457887 (UMLS CUI [2,1])
C0236124 (UMLS CUI [2,2])
C0028778 (UMLS CUI [3,1])
C1514873 (UMLS CUI [3,2])
C2034480 (UMLS CUI [3,3])
C0028778 (UMLS CUI [4,1])
C1514873 (UMLS CUI [4,2])
C0030547 (UMLS CUI [4,3])
Abdominal fistula | Gastrointestinal perforation | Abdominal Abscess
Item
8. history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of first dose of bevacizumab
boolean
C1879311 (UMLS CUI [1])
C0151664 (UMLS CUI [2])
C0243001 (UMLS CUI [3])
Peripheral Arterial Disease
Item
9. clinically significant peripheral artery disease
boolean
C1704436 (UMLS CUI [1])
Thromboembolic event Arterial | Transient Ischemic Attack | Cerebrovascular accident | Angina, Unstable | Myocardial Infarction
Item
10. arterial thromboembolic event within the past 6 months, including transient ischemic attack, cerebrovascular accident, unstable angina, or myocardial infarction
boolean
C0040038 (UMLS CUI [1,1])
C0221464 (UMLS CUI [1,2])
C0007787 (UMLS CUI [2])
C0038454 (UMLS CUI [3])
C0002965 (UMLS CUI [4])
C0027051 (UMLS CUI [5])
Hemoptysis Gross
Item
11. history of gross hemoptysis (i.e. ≥ 1 teaspoon of bright red blood)
boolean
C0019079 (UMLS CUI [1,1])
C0439806 (UMLS CUI [1,2])
Cancer Other | Exception Basal cell carcinoma Cured | Exception Squamous cell carcinoma of skin Cured | Exception Carcinoma in situ of uterine cervix Cured
Item
12. other malignancy within 5 years except cured basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1880198 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0553723 (UMLS CUI [3,2])
C1880198 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0851140 (UMLS CUI [4,2])
C1880198 (UMLS CUI [4,3])
Mental disorders Exclude Protocol Compliance | Social situation Excludes Protocol Compliance
Item
13. psychiatric illness or social situation that would preclude study compliance
boolean
C0004936 (UMLS CUI [1,1])
C0332196 (UMLS CUI [1,2])
C0525058 (UMLS CUI [1,3])
C0748872 (UMLS CUI [2,1])
C0332196 (UMLS CUI [2,2])
C0525058 (UMLS CUI [2,3])
Non healing wound Serious | Ulcer | Bone fracture
Item
14. serious non-healing wound, ulcer, or bone fracture
boolean
C0750433 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0041582 (UMLS CUI [2])
C0016658 (UMLS CUI [3])
Major surgery | Incisional biopsy | Traumatic injury
Item
15. major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment
boolean
C0679637 (UMLS CUI [1])
C0184922 (UMLS CUI [2])
C3263723 (UMLS CUI [3])
Minor Surgical Procedures | Needle biopsy
Item
16. prior minor surgery or needle biopsies within 7 days
boolean
C0038904 (UMLS CUI [1])
C0005560 (UMLS CUI [2])
Aspirin chronic Daily Dose | Dipyridamole | Ticlopidine | clopidogrel | cilostazol | Non-Steroidal Anti-Inflammatory Agents Inhibiting Platelet function
Item
17. concurrent chronic daily aspirin (> 325 mg/day), dipyridamole, ticlopidine, clopidogrel, cilostazol, non-steroidal anti-inflammatory agents known to inhibit platelet function
boolean
C0004057 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C2348070 (UMLS CUI [1,3])
C0012582 (UMLS CUI [2])
C0040207 (UMLS CUI [3])
C0070166 (UMLS CUI [4])
C0055729 (UMLS CUI [5])
C0003211 (UMLS CUI [6,1])
C3463820 (UMLS CUI [6,2])
C1254881 (UMLS CUI [6,3])
Anticoagulation Therapy | Prophylactic anticoagulation Venous access allowed
Item
18. concurrent therapeutic anticoagulation, but prophylactic anti-coagulation of venous access devices is allowed
boolean
C0003281 (UMLS CUI [1])
C4304154 (UMLS CUI [2,1])
C0750164 (UMLS CUI [2,2])
C0683607 (UMLS CUI [2,3])
Allergic Reaction Compound Investigational New Drug Similar
Item
19. history of allergic reaction to compounds of similar chemical composition to the study drugs
boolean
C1527304 (UMLS CUI [1,1])
C0205198 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,3])
C2348205 (UMLS CUI [1,4])
Pregnancy | Breast Feeding
Item
20. pregnancy or lactation
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])